


Express Mail Label No.: EL86265062US

Date of Deposit: October 11, 2001



PATENT APPLICATION
Attorney Docket No. 21486-03

RECEIVED
OCT 17 2001
TECHNICAL CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Calabresi, *et al.*

SERIAL NUMBER: 09/802,094

EXAMINER: Not Yet Assigned

FILING DATE: March 8, 2001

ART UNIT: 1614

FOR: COMBINATION DRUG STUDY

October 11, 2001
Boston, Massachusetts

Assistant Commissioner for Patents
Washington, D.C. 20231

PRELIMINARY AMENDMENT

In response to the September 7, 2001 Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, Applicants file this Preliminary Amendment. Please amend the application as set forth below and consider the following remarks:

Applicants believe that no fee is required for the filing of the present paper. However, the Commissioner is hereby authorized to charge any additional fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference 21486-038.

In the Specification:

Please insert the Sequence Listing, pages 1-4, at the end of the specification.

REMARKS

Applicants submit a Sequence Listing for the nucleotide sequences disclosed in the specification, in compliance with the requirements for patent applications containing nucleotide sequences and/or amino acid sequence disclosures. 37 C.F.R. §§ 1.821-1.825. No new matter is added.

Applicants: Calabresi.
U.S.S.N. 09/802,094

CONCLUSION

Applicants respectfully submit that the present application complies with the requirements set forth in 37 C.F.R. §§ 1.821-1.825. If there are any questions regarding these amendments and remarks, the Examiner is encouraged to contact the undersigned at the telephone number provided below.

Respectfully submitted,



Date: October 11, 2001

Ingrid A. Beattie, Reg. No. 42,306
c/o Mintz, Levin
One Financial Center
Boston, MA 02111
Telephone (617) 542 6000
Fax (617) 542 2241

TRA 1575162v1